The Alexion settlement removes a major overhang and provides $105M in cash, extending runway through 2028. Key catalysts ahead: XmAb819 ESMO oral presentation (Oct 2026) and XENITH-UC interim analysis (year-end 2026). The XmAb541 Fast Track designation adds regulatory optionality. Monitor for potential partnership interest in the TL1A franchise (XmAb942/XmAb412) given the competitive landscape.
Price Chart
Executive Summary
Xencor reported Q2 2026 revenue of $51.2M (vs $18.9M consensus) and EPS of -$0.29 (vs -$0.84 consensus), a significant beat driven by a $27.6M royalty catch-up from the Alexion Ultomiris settlement and a $10M Zenas milestone. The company raised its year-end cash guidance to $420M-$440M (from $380M-$400M) and extended its cash runway through 2028. Pipeline milestones remain on track with XmAb819 ESMO data and XmAb942 XENITH-UC interim analysis expected by year-end.
Key Financial Metrics
Key Facts
- Revenue of $51.2M beat consensus of $18.9M by 171%
- EPS of -$0.29 beat consensus of -$0.84 by 65.6%
- Net loss narrowed to -$21.7M from -$30.8M YoY
- Raised year-end 2026 cash guidance to $420M-$440M from $380M-$400M
- Cash runway extended through 2028
- Alexion settlement provides $105M total ($52.5M due Aug 2026, $52.5M in 2027)
- XmAb819 ccRCC data accepted for oral presentation at ESMO Oct 2026
- XmAb942 XENITH-UC blinded interim analysis on track for year-end 2026
- XmAb541 granted FDA Fast Track designation for germ cell tumors
- XmAb412 first-in-human study initiated in Q3 2026
Financial Impact
Revenue beat of $32.3M vs consensus, driven by $27.6M Alexion royalty catch-up and $10M Zenas milestone; net loss improved by $9.1M YoY; cash guidance raised by $40M
Risk Factors
- XmAb541 hearing impairment toxicity could limit commercial potential despite Fast Track designation
- XmAb942 XENITH-UC Phase 2b data risk — TL1A space is competitive with Roche/Teva and Merck/Prometheus
- Revenue is lumpy and dependent on partnership milestones and royalty settlements
- Operating burn rate increasing ($71.9M R&D in Q2 vs $61.7M YoY)
- No approved products — all value is in pipeline optionality
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000055 |
| Document: xncr-20260805.htm | 0001326732-26-000055 |
| Document: 0001326732-26-000055-index-headers.html | 0001326732-26-000055 |
| Document: 0001326732-26-000055-index.html | 0001326732-26-000055 |
| Document: 0001326732-26-000055.txt | 0001326732-26-000055 |
| 8-K Data (Synthetic) | 0001326732-26-000055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $20.00 $26.62 | ▲ +33.10% | ▲ +32.50% | $24.31 (+21.55%) |
Jun 17, 2026 15w ago | Insider Cluster | $12.64 $14.95 | ▲ +18.28% | ▲ +17.74% | $24.31 (+92.33%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $24.31 (+99.10%) |
Jun 15, 2026 15w ago | 144 | $12.21 $14.96 | ▲ +22.52% | ▲ +23.27% | $24.31 (+99.10%) |
May 6, 2026 21w ago | 8-K | $12.31 $11.42 | ▲ +7.23% | ▲ +10.37% | $24.31 (−97.48%) |
May 5, 2026 21w ago | 8-K | $12.85 $11.21 | ▼ −12.76% | ▼ −17.72% | $24.31 (+89.18%) |
Apr 27, 2026 22w ago | 8-K | $12.15 $11.63 | ▼ −4.28% | ▼ −9.75% | $24.31 (+100.08%) |
Mar 5, 2026 30w ago | Insider Cluster | $11.16 $12.81 | ▲ +14.78% | ▲ +18.57% | $24.31 (+117.83%) |
Mar 4, 2026 30w ago | 8-K | $11.16 $12.81 | ▼ −14.78% | ▼ −18.57% | $24.31 (−117.83%) |
Feb 25, 2026 31w ago | 8-K | $11.98 $12.40 | ▲ +3.51% | ▲ +8.74% | $24.31 (+102.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access